Amgen Inc. (NASDAQ:AMGN – Free Report) – Analysts at Cantor Fitzgerald decreased their FY2025 earnings per share estimates for Amgen in a report issued on Thursday, October 9th. Cantor Fitzgerald analyst C. Gould now forecasts that the medical research company will earn $21.30 per share for the year, down from their previous forecast of $21.35. Cantor Fitzgerald currently has a “Neutral” rating and a $305.00 target price on the stock. The consensus estimate for Amgen’s current full-year earnings is $20.62 per share.
Amgen (NASDAQ:AMGN – Get Free Report) last issued its quarterly earnings results on Tuesday, August 5th. The medical research company reported $6.02 earnings per share (EPS) for the quarter, beating the consensus estimate of $5.28 by $0.74. Amgen had a return on equity of 174.71% and a net margin of 18.96%.The business had revenue of $9.18 billion for the quarter, compared to analyst estimates of $8.86 billion. During the same quarter in the prior year, the firm posted $4.97 earnings per share. The firm’s revenue for the quarter was up 9.4% compared to the same quarter last year. Amgen has set its FY 2025 guidance at 20.200-21.300 EPS.
View Our Latest Stock Analysis on AMGN
Amgen Trading Up 0.5%
NASDAQ:AMGN opened at $293.85 on Monday. Amgen has a 1-year low of $253.30 and a 1-year high of $335.88. The business’s 50-day moving average price is $286.46 and its two-hundred day moving average price is $287.37. The company has a current ratio of 1.31, a quick ratio of 0.98 and a debt-to-equity ratio of 7.24. The firm has a market capitalization of $158.20 billion, a price-to-earnings ratio of 24.03, a PEG ratio of 2.54 and a beta of 0.49.
Amgen Dividend Announcement
The firm also recently declared a quarterly dividend, which was paid on Friday, September 12th. Stockholders of record on Friday, August 22nd were given a dividend of $2.38 per share. The ex-dividend date of this dividend was Friday, August 22nd. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.2%. Amgen’s dividend payout ratio (DPR) is currently 77.84%.
Insider Activity at Amgen
In other news, SVP Nancy A. Grygiel sold 1,267 shares of the firm’s stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $296.99, for a total transaction of $376,286.33. Following the sale, the senior vice president owned 7,209 shares of the company’s stock, valued at $2,141,000.91. This trade represents a 14.95% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through this hyperlink. 0.69% of the stock is currently owned by corporate insiders.
Institutional Investors Weigh In On Amgen
A number of hedge funds have recently modified their holdings of the business. Brighton Jones LLC grew its holdings in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock worth $7,159,000 after buying an additional 5,226 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Amgen by 40.2% during the first quarter. GAMMA Investing LLC now owns 11,753 shares of the medical research company’s stock worth $3,662,000 after buying an additional 3,369 shares in the last quarter. Goldstone Financial Group LLC bought a new position in shares of Amgen during the first quarter worth about $239,000. Griffin Asset Management Inc. bought a new position in shares of Amgen during the first quarter worth about $230,000. Finally, Tritonpoint Wealth LLC grew its holdings in shares of Amgen by 5.7% during the first quarter. Tritonpoint Wealth LLC now owns 1,828 shares of the medical research company’s stock worth $569,000 after buying an additional 99 shares in the last quarter. Institutional investors and hedge funds own 76.50% of the company’s stock.
About Amgen
Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.
Further Reading
- Five stocks we like better than Amgen
- Stock Sentiment Analysis: How it Works
- After Gold Blast Soars Past $4,000, BofA Eyes $5,000 in 2026
- Where to Find Earnings Call Transcripts
- Buyback Boom: 3 Companies Betting Big on Themselves
- Dividend Screener: How to Evaluate Dividend Stocks Before Buying
- Analysts Flock to Upgrade DELL After Big AI-Server Guidance Boost
Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.